← Back to Screener
Apellis Pharmaceuticals, Inc. Common Stock (APLS)
Price$41.03
Value ScoreD
Growth ScoreB
Momentum ScoreA
Favorite Metrics
Price vs S&P 500 (26W)96.11%
Price vs S&P 500 (4W)-5.40%
VGM Score64.94
Market Capitalization$5.25B
P/E Ratio (Annual)234.62x
All Metrics
P/CF (Annual)115.88x
Book Value / Share (Quarterly)$3.24
P/TBV (Annual)33.76x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)137.00%
Cash Flow / Share (Quarterly)$0.29
Price vs S&P 500 (YTD)54.48%
Gross Margin (TTM)90.19%
Net Profit Margin (TTM)12.06%
EPS (TTM)$1.00
10-Day Avg Trading Volume11.48M
EPS Excl Extra (TTM)$1.00
Revenue Growth (5Y)31.99%
EPS (Annual)$0.18
ROI (Annual)2.71%
Gross Margin (Annual)89.81%
Net Profit Margin (5Y Avg)-428.42%
Cash / Share (Quarterly)$3.17
P/E Basic Excl Extra (TTM)39.41x
Revenue Growth QoQ (YoY)60.85%
P/E Normalized (Annual)234.62x
ROA (Last FY)2.08%
Revenue Growth TTM (YoY)42.46%
EBITD / Share (TTM)$1.30
ROE (5Y Avg)-222.36%
Operating Margin (TTM)14.95%
Cash Flow / Share (Annual)$0.36
P/B Ratio12.66x
P/B Ratio (Quarterly)12.40x
Net Income / Employee (Annual)$30,500
EV / Revenue (TTM)4.80x
Net Interest Coverage (TTM)1.77x
ROA (TTM)13.20%
EV / EBITDA (TTM)31.83x
EPS Incl Extra (Annual)$0.18
Current Ratio (Annual)3.14x
Quick Ratio (Quarterly)3.01x
3-Month Avg Trading Volume5.45M
52-Week Price Return137.44%
EV / Free Cash Flow (Annual)117.82x
P/E Incl Extra (TTM)39.41x
Revenue / Employee (TTM)$1,507,900
Tangible BV / Share (Quarterly)$1.96
P/S Ratio (Annual)5.23x
Asset Turnover (Annual)0.93x
52-Week High$41.14
Operating Margin (5Y Avg)-386.90%
EPS Excl Extra (Annual)$0.18
CapEx CAGR (5Y)-43.47%
Tangible BV CAGR (5Y)2.66%
26-Week Price Return105.66%
Quick Ratio (Annual)2.59x
13-Week Price Return81.71%
Total Debt / Equity (Annual)1.23x
Current Ratio (Quarterly)3.63x
Enterprise Value$5.30B
Revenue / Share Growth (5Y)19.02%
Asset Turnover (TTM)1.09x
Book Value / Share Growth (5Y)1.69%
Revenue / Employee (Annual)$1,369,400
Inventory Turnover (Annual)0.91x
Pretax Margin (Annual)2.40%
Cash / Share (Annual)$3.68
3-Month Return Std Dev268.65%
Gross Margin (5Y Avg)88.95%
Net Income / Employee (TTM)$181,800
ROE (Last FY)6.05%
Net Interest Coverage (Annual)5.48x
EPS Basic Excl Extra (Annual)$0.18
P/FCF (TTM)39.78x
Receivables Turnover (TTM)3.27x
EV / Free Cash Flow (TTM)141.55x
Total Debt / Equity (Quarterly)1.10x
EPS Incl Extra (TTM)$1.00
Receivables Turnover (Annual)3.18x
ROI (TTM)16.86%
P/S Ratio (TTM)4.75x
Pretax Margin (5Y Avg)-427.94%
Revenue / Share (Annual)$7.96
Tangible BV / Share (Annual)$1.53
Price vs S&P 500 (52W)110.95%
P/E Ratio (TTM)39.41x
Year-to-Date Return63.34%
5-Day Price Return0.05%
EPS Normalized (Annual)$0.18
ROA (5Y Avg)-51.55%
Net Profit Margin (Annual)2.23%
Month-to-Date Return0.20%
Cash Flow / Share (TTM)$-5.21
EBITD / Share (Annual)$0.45
Operating Margin (Annual)5.52%
LT Debt / Equity (Annual)0.98x
P/CF (TTM)139.07x
ROI (5Y Avg)-64.42%
P/E Excl Extra (TTM)39.41x
LT Debt / Equity (Quarterly)0.87x
EPS Basic Excl Extra (TTM)$1.00
P/TBV (Quarterly)24.69x
P/B Ratio (Annual)8.59x
Inventory Turnover (TTM)1.01x
Pretax Margin (TTM)12.23%
Book Value / Share (Annual)$2.92
Price vs S&P 500 (13W)74.46%
Beta0.63x
P/FCF (Annual)116.69x
Revenue / Share (TTM)$8.41
ROE (TTM)39.71%
52-Week Low$16.83
vGradeD
gGradeB
mGradeA
vgmGradeB
Show chart for
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
3.96
3.93
3.56
3.41
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
APLSApellis Pharmaceuticals, Inc. Common Stock | D | B | A | $41.03 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Apellis Pharmaceuticals commercializes complement system inhibitors for diseases with significant unmet treatment needs. The company markets two C3-targeted therapies, SYFOVRE and EMPAVELI (both pegcetacoplan-based), which inhibit a central immune pathway and represent meaningful commercial opportunities in complement-driven immune diseases.